2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Newborn Screening, Omics Technologies, Pathology, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Surgical, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

6109 Accurate T- and B-cell clonality inference from comprehensive genomic profiling by targeted sequencing

Amirsaman Ashtari, PhD, Navika Shukla, MD2, Lena Osswald, MD3, Takeshi Sugio, MD, PhD4, Stefan Alig, MD5, Joe Gaillard Schroers-Martin, MD6, Ash A. Alizadeh, MD, PhD7, Henning Stehr, MD8, Mohammad Shahrokh Esfahani, PhD9
1 Stanford University, Palo Alto, United States
2 Stanford University, Palo Alto, United States
3 Stanford University, Palo Alto, United States
4 Stanford University, Palo Alto, United States
5 University Hospital Essen, Essen, Germany
6 Stanford University, Palo Alto, United States
7 Stanford University, Palo Alto, United States
8 Stanford University, Palo Alto, United States
9 Stanford University, Palo Alto, United States

Background. Immune-receptor clonality testing is often used for diagnosis and monitoring of lymphoid malignancies but generally requires dedicated V(D)J assays to interrogate B- and T-cell receptor (BCR/TCR) recombinations. We developed J-TRACE to recover clonality information from Heme-STAMP, Stanford’s institutional comprehensive tumor-genotyping panel for hematolymphoid malignancies, by exploiting its IGH and TCR J-segment coverage together with off-target/unmapped reads, and now share this resource.

Methods. We analyzed 1,328 tissue specimens from 977 Heme-STAMP profiled patients at ~2,000× median depth. T-cell lymphomas, DLBCL, FL, and myeloma comprised the most prevalent lymphoid tumor types accounting for ~30% of cases. Of these 1,328 cases, 942 (71%) had clonal status available by an orthogonal assay (Invivoscribe LymphoTrack) for training/validation, with the remaining 386 (29%) used for additional validation by malignancy type.

We developed J-TRACE to retrieve reads overlapping J segments, their mates, unmapped reads, and off-target reads at V loci, and to refine mappings to 1,169 IMGT V- and J-region alleles by BLAST, assembling fixed VJ-pairings with per-chain V×J fragment-count matrices for TRB/G and IGH/K. These count matrices were further summarized into 76 to 392 features to train a probabilistic BCR/TCR clonality model through an ensemble machine learning framework. The performance of J-TRACE was then evaluated by cross-validation. As a comparison, MiXCR was benchmarked on identical reads from 400 balanced specimens.

Results. For TCR clonality analysis (TRB/G), we studied 842 specimens (337 nonclonal, 128 oligoclonal, 377 clonal), and for BCR clonality analysis (IGH/K), we studied 358 specimens (213 nonclonal, 4 oligoclonal, 141 clonal). Among specimens with TRB scores, maximum clone abundance increased monotonically from 7.8% in nonclonal to 15% in oligoclonal and 26.8% in clonal specimens (Kruskal-Wallis P<<0.001), supporting oligoclonality as an intermediate state; similar trends were seen for BCR clonality.

Among features used by J-TRACE, maximal VxJ clone fraction (TRB) and VxJ Gini (TRG/IGH/IGK) had best clonality discriminatory power (corresponding AUCs of 0.801, 0.736, 0.607, 0.683), with rising performance seen as a function of junctional depth. J-TRACE-TCR achieved AUC ~0.86, with a paired AUC gain of 0.033 over TRB maximal clone fraction, corresponding to 68% sensitivity at 90% specificity. J-TRACE-BCR achieved an AUC of 0.76. Gains were greatest in bone marrow and FFPE specimens, whereas high-depth peripheral-blood specimens derived little incremental benefit. 

Against MiXCR on identical reads, repertoire burden correlated strongly (Spearman ρ=0.74; p<0.001); at matched V×J resolution, J-TRACE and MiXCR were statistically equivalent. Full-CDR3 MiXCR had numerically but not statistically higher AUC for V×J representation than J-TRACE (0.862 vs 0.826; P=0.22), indicating that capture and V×J resolution, rather than assignment, are limiting. Additional favorable benchmarking comparisons to existing methods including MiXCR and SABER for the entire cohort will be presented.

Finally, we applied J-TRACE to the remaining 386 specimens, consisting of TCL (n=63), DLBCL (n=160), FL (n=94), and MCL (n=69). We observed a striking contrast in inferred BCR clonality among B-cell malignancies of decreasing tumor purity (MCL=0.957, DLBCL=0.687, FL=0.502; p=6.5 × 10⁻¹⁸). Conversely, the inferred TCR clonality was significantly higher in TCL tumors compared with B-cell neoplasms (0.411 versus 0.291; p=0.0316).

Conclusions: J-TRACE allows accurate and quantitative T- and B-cell clonality measurements from routine comprehensive genome profiling, without an additional assay, tissue requirement, or sequencing run. J-anchored capture preserves an ordered biological signal enabling J-TRACE to achieve performance improvements. While J-TRACE is not intended to replace dedicated clonality testing, as a shared resource (URL pending), it accurately identifies likely clonal, likely nonclonal, and lower-confidence specimens for confirmatory standard of care testing.

Amirsaman Ashtari, PhD: No relevant conflicts of interest to declare.